Transarterial chemoembolization with/without immune checkpoint inhibitors plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a single center, propensity score matching real-world study

被引:2
|
作者
Yuan, Guosheng [1 ]
Li, Wenli [1 ]
Zang, Mengya [1 ]
Li, Rong [1 ]
Li, Qi [1 ]
Hu, Xiaoyun [1 ]
Zhang, Qi [1 ]
Huang, Wei [2 ]
Ruan, Jian [3 ]
Pang, Huajin [4 ]
Chen, Jinzhang [1 ]
机构
[1] Southern Med Univ, Nanfang Hosp, Dept Infect Dis, State Key Lab Organ Failure Res, Guangzhou 510515, Guangdong, Peoples R China
[2] Southern Med Univ, Shunde Hosp, Dept Oncol, Shunde 528300, Guangdong, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Med Oncol, Hangzhou 310003, Zhejiang, Peoples R China
[4] Southern Med Univ, Nanfang Hosp, Dept Gen Surg, Div Vasc & Intervent Radiol, Guangzhou 510515, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
Hepatocellular carcinoma; TACE; Immune checkpoint inhibitors; Tyrosine kinase inhibitors; Overall survival; MICROENVIRONMENT; BEVACIZUMAB; SORAFENIB; TACE;
D O I
10.1007/s12672-024-00917-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives To explore the efficacy and safety of Transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) in patients with unresectable hepatocellular carcinoma (uHCC). Methods 456 patients with HCC receiving either TACE in combination with ICIs and TKIs (combination group, n = 139) or TACE monotherapy (monotherapy group, n = 317) were included from Apr 2016 to Dec 2021 in this retrospective study. We employed propensity score matching (PSM), performed 1:2 optimal pair matching, to balance potential bias. Results The mean follow-up time is 24.7 months (95% CI 22.6-26.8) for matched patients as of March 2022. After matching, the combination group achieved longer OS and PFS (median OS:21.9 vs. 16.3 months, P = 0.022; median PFS: 8.3 vs. 5.1 months, P < 0.0001) than TACE monotherapy group. The combination group had better objective response rate (ORR) and disease control rate (DCR) (ORR: 52.5% vs. 32.8%, P < 0.001; DCR: 82.7% vs. 59.6%, P < 0.001). Subgroup analysis showed that patients who received "TKIs + ICIs" after the first TACE procedure (after TACE group) achieved longer OS than those before the first TACE procedure (before TACE group) (26.8 vs. 19.2 months, P = 0.011). Adverse events were consistent with previous studies of TACE-related trials. Conclusions TACE plus TKIs and ICIs appeared to deliver longer PFS and OS in HCC patients than TACE monotherapy. "TKIs + ICIs" co-treatment within 3 months after the first TACE procedure might be a better medication strategy.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Tyrosine kinase inhibitors plus immune checkpoint inhibitors as neoadjuvant therapy for hepatocellular carcinoma: an emerging option?
    Rizzo, Alessandro
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2022, 31 (04) : 333 - 335
  • [42] Transarterial chemoembolization plus lenvatinib with or without immune checkpoint inhibitors for advanced hepatocellular carcinoma: A meta-analysis and systematic review
    Zhang, W.
    Yin, Y.
    Che, X.
    ANNALS OF ONCOLOGY, 2024, 35 : S81 - S81
  • [43] Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab or Lenvatinib for Unresectable Hepatocellular Carcinoma: A Propensity Score Matched Study
    Zhao, Chenghao
    Xiang, Zhanwang
    Li, Mingan
    Wang, Haofan
    Liu, Huan
    Yan, Huzheng
    Huang, Mingsheng
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2023, 10 : 1195 - 1206
  • [44] Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization Combining Immune Checkpoint Inhibitors in Unresectable Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis
    Yang, Xue-Gang
    Sun, Yan-Yuan
    Li, De-Shan
    Xu, Guo-Hui
    Huang, Xiao-Qi
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [45] The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review
    Ke, Qiao
    Xin, Fuli
    Fang, Huipeng
    Zeng, Yongyi
    Wang, Lei
    Liu, Jingfeng
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [46] A real-world study of tyrosine kinase inhibitors plus anti-PD-1 immunotherapy with or without chemoembolization for hepatocellular carcinoma patients with main portal vein invasion
    Song, Ze
    Wu, De-Di
    Fan, Wen-Zhe
    Wu, Min-Jiang
    Miao, Hong-Fei
    Du, Jia-Hang
    Zhang, Hao
    Jiang, Dai-Rong
    Zhang, Ying-Qiang
    ABDOMINAL RADIOLOGY, 2024, 49 (08) : 2650 - 2658
  • [47] Efficacy and Safety of Transarterial Chemoembolization Plus Lenvatinib with or Without Tislelizumab as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
    Jiang, Jiayun
    Zhang, Hui
    Lai, Jiejuan
    Zhang, Shiyu
    Ou, Yanjiao
    Fu, Yu
    Zhang, Leida
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2024, 11 : 1607 - 1622
  • [48] Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibodies with Hepatic Arterial Infusion Chemotherapy or Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma
    Yu, Bingran
    Zhang, Ning
    Feng, Yun
    Zhang, Yongfa
    Zhang, Ti
    Wang, Lu
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2023, 10 : 1735 - 1748
  • [49] Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma
    Li, Jinpeng
    Kong, Mingxin
    Yu, Guangji
    Wang, Song
    Shi, Zhaozhang
    Han, Huihui
    Lin, Yanyan
    Shi, Jutian
    Song, Jinlong
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [50] Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma
    Li, Jinpeng
    Jia, Yuntao
    Han, Huihui
    Lin, Yanyan
    Song, Jinlong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)